You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cardiovascular conditions
  5. Acute coronary syndromes

Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes

  • Technology appraisal guidance
  • Reference number: TA47
  • Published:  05 September 2002
  • Last updated:  01 March 2010
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 Clinical need and practice
  • 3 The technology
  • 4 Evidence and interpretation
  • 5 Recommendations for further research
  • 6 Implications for the NHS
  • 7 Implementation and audit
  • 8 Appraisal committee members
  • 9 Sources of evidence considered by the committee
  • 10 Detail on criteria for audit of the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
  • Update information

Update information

March 2010: This guidance was partially updated by NICE's guideline on acute coronary syndromes.

ISBN: 978-1-4731-5633-3


Previous page 10 Detail on criteria for audit of the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
Back to top